GlassScriptPhysician profile
Bedoor Alabbas
NPI 1952751182
$4,261.68
in general payments reported to CMS, 2019-2025
27 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2022: $483 · 2023: $1,043 · 2024: $919 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,664.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,687.85 | 2022-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $518.85 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $311.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.62 | 2022-2025 | Entyvio, Vpriv |
| Madrigal Pharmaceuticals | $162.40 | 2025 | Rezdiffra |
| Celgene Corporation | $144.87 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $143.18 | 2025 | Overstitch Endoscopic Suturing System |
| Aimmune Therapeutics, INC. | $131.18 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.05 | 2022-2024 | Xifaxan |
| Ardelyx, INC. | $99.79 | 2023-2025 | Ibsrela |
| Pfizer INC. | $94.68 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $89.88 | 2023-2025 | Terlivaz |
| Ferring Pharmaceuticals INC. | $60.95 | 2022-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $60.16 | 2024-2025 | Voquezna |
| Amgen INC. | $53.05 | 2023 | Avsola, Amjevita |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $52.05 | 2022-2023 | Givlaari |
| Novo Nordisk INC | $48.31 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $41.66 | 2023 | |
| Merck Sharp & Dohme LLC | $39.88 | 2023 | Dificid |
| Qol Medical, LLC | $36.66 | 2023 | Sucraid |
| Celltrion USA INC. | $32.27 | 2025 | Vegzelma |
| Genzyme Corporation | $30.16 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $27.10 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $24.59 | 2023 | Sutab |
| Organon LLC | $20.07 | 2023 | Hadlima, Renflexis |
| Sandoz INC. | $16.20 | 2024 | Hyrimoz |
| W. L. Gore & Associates, INC. | $14.59 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bedoor Alabbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.